This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kosakowska-Cholody, T. Articles by Michejda, C. J. Search for Related Content PubMed PubMed Citation Articles by Kosakowska-Cholody, T. Articles by Michejda, C. J.

¹ Molecular Aspects of Drug Design, Structural Biophysics Laboratory, Center for Cancer Research; ² Screening Technologies Branch, Laboratory of Functional Genomics, Science Applications International Corporation, National Cancer Institute at Frederick, Frederick, Maryland; and ³ Department of Radiation Oncology, University of Texas Health Science Center, San Antonio, Texas

Requests for reprints: Christopher J. Michejda, Molecular Aspects of Drug Design, Structural Biophysics Laboratory, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702. Phone: 301-846-1216; Fax: 301-846-6231. E-mail: michejda{at}ncifcrf.gov

WMC-79 is a synthetic agent with potent activity against colon and hematopoietic tumors. In vitro, the agent is most potent against colon cancer cells that carry the wild-type p53 tumor suppressor gene (HCT-116 and RKO cells: GI₅₀ <1 nmol/L, LC₅₀ 40 nmol/L). Growth arrest of HCT-116 and RKO cells occurs at the G₁ and G₂-M check points at sublethal concentrations (10 nmol/L) but the entire cell population was killed at 100 nmol/L. WMC-79 is localized to the nucleus where it binds to DNA. We hypothesized that WMC-79 binding to DNA is recognized as an unrepairable damage in the tumor cells, which results in p53 activation. This triggers transcriptional up-regulation of p53-dependent genes involved in replication, cell cycle progression, growth arrest, and apoptosis as evidenced by DNA microarrays. The change in the transcriptional profile of HCT-116 cells is followed by a change in the levels of cell cycle regulatory proteins and apoptosis. The recruitment of the p53-dependent apoptosis pathway was suggested by the up-regulation of p53, p21, Bax, DR-4, DR-5, and p53 phosphorylated on Ser15; down-regulation of Bcl-2; and activation of caspase-8, -9, -7, and -3 in cells treated with 100 nmol/L WMC-79. Apoptosis was also evident from the flow cytometric studies of drug-treated HCT-116 cells as well as from the appearance of nuclear fragmentation. However, whereas this pathway is important in wild-type p53 colon tumors, other pathways are also in operation because colon cancer cell lines in which the p53 gene is mutated are also affected by higher concentrations of WMC-79.

This article has been cited by other articles:

				M. LaFevre-Bernt, S. Wu, and X. Lin Recombinant, refolded tetrameric p53 and gonadotropin-releasing hormone-p53 slow proliferation and induce apoptosis in p53-deficient cancer cells Mol. Cancer Ther., June 1, 2008; 7(6): 1420 - 1429. [Abstract] [Full Text] [PDF]

				V. M. Arlt, E. Frei, and H. H. Schmeiser ECNIS-sponsored workshop on biomarkers of exposure and cancer risk: DNA damage and DNA adduct detection and 6th GUM-32P-postlabelling workshop, German Cancer Research Center, Heidelberg, Germany, 29-30 September 2006 Mutagenesis, January 1, 2007; 22(1): 83 - 88. [Abstract] [Full Text] [PDF]